AU2019291794B2 - Substituted naphthyridinone compounds useful as T cell activators - Google Patents

Substituted naphthyridinone compounds useful as T cell activators Download PDF

Info

Publication number
AU2019291794B2
AU2019291794B2 AU2019291794A AU2019291794A AU2019291794B2 AU 2019291794 B2 AU2019291794 B2 AU 2019291794B2 AU 2019291794 A AU2019291794 A AU 2019291794A AU 2019291794 A AU2019291794 A AU 2019291794A AU 2019291794 B2 AU2019291794 B2 AU 2019291794B2
Authority
AU
Australia
Prior art keywords
methyl
oxo
dihydro
naphthyridine
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2019291794A
Other languages
English (en)
Other versions
AU2019291794A1 (en
Inventor
Louis S. Chupak
Chetan Padmakar Darne
Bireshwar Dasgupta
Min Ding
Robert G. Gentles
Yazhong Huang
Prasada Rao JALAGAM
Manjunatha Narayana Rao Kamble
Raju MANNOORI
Scott W. Martin
Ivar M. Mcdonald
Richard E. Olson
Hasibur RAHAMAN
Thiruvenkadam RAJA
Kotha Rathnakar REDDY
Saumya Roy
John S. Tokarski
Gopikishan TONUKUNURU
Sivasudar Velaiah
Upender Velaparthi
Jayakumar Sankara WARRIER
Xiaofan Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2019291794A1 publication Critical patent/AU2019291794A1/en
Application granted granted Critical
Publication of AU2019291794B2 publication Critical patent/AU2019291794B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
AU2019291794A 2018-06-27 2019-06-26 Substituted naphthyridinone compounds useful as T cell activators Ceased AU2019291794B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862690439P 2018-06-27 2018-06-27
US62/690,439 2018-06-27
US201962840459P 2019-04-30 2019-04-30
US62/840,459 2019-04-30
PCT/US2019/039135 WO2020006018A1 (en) 2018-06-27 2019-06-26 Substituted naphthyridinone compounds useful as t cell activators

Publications (2)

Publication Number Publication Date
AU2019291794A1 AU2019291794A1 (en) 2021-02-11
AU2019291794B2 true AU2019291794B2 (en) 2022-06-16

Family

ID=67439335

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019291794A Ceased AU2019291794B2 (en) 2018-06-27 2019-06-26 Substituted naphthyridinone compounds useful as T cell activators

Country Status (28)

Country Link
US (3) US10669272B2 (enExample)
EP (1) EP3814348B9 (enExample)
JP (1) JP7432532B2 (enExample)
KR (1) KR102767739B1 (enExample)
CN (1) CN112654621B (enExample)
AU (1) AU2019291794B2 (enExample)
BR (1) BR112020026681A2 (enExample)
CA (1) CA3104654A1 (enExample)
CL (1) CL2020003260A1 (enExample)
CY (1) CY1126280T1 (enExample)
DK (1) DK3814348T3 (enExample)
ES (1) ES2960754T3 (enExample)
FI (1) FI3814348T3 (enExample)
HR (1) HRP20231253T1 (enExample)
HU (1) HUE064531T2 (enExample)
IL (1) IL279728B2 (enExample)
LT (1) LT3814348T (enExample)
MX (1) MX2020013817A (enExample)
PE (1) PE20210469A1 (enExample)
PL (1) PL3814348T3 (enExample)
PT (1) PT3814348T (enExample)
RS (1) RS64641B1 (enExample)
SG (1) SG11202012972YA (enExample)
SI (1) SI3814348T1 (enExample)
SM (1) SMT202300466T1 (enExample)
TW (1) TW202019924A (enExample)
WO (1) WO2020006018A1 (enExample)
ZA (1) ZA202100555B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111471059B (zh) * 2019-01-23 2022-12-02 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
JP7574215B2 (ja) 2019-04-29 2024-10-28 ソレント セラピューティクス，エルエルシー ＭＲＧＸ２の阻害薬である３－アミノ－４Ｈ－ベンゾ［ｅ］［１，２，４］チアジアジン１，１－ジオキシド誘導体
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
EP4065584A1 (en) 2019-11-28 2022-10-05 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
WO2021105115A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
US12478621B2 (en) 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
WO2021127554A1 (en) * 2019-12-19 2021-06-24 Bristol-Myers Squibb Company Combinations of dgk inhibitors and checkpoint antagonists
JP7677976B2 (ja) * 2019-12-23 2025-05-15 ブリストル－マイヤーズ スクイブ カンパニー Ｔ細胞アクティベーターとして有用な置換ヘテロアリール化合物
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
MX2022007369A (es) * 2019-12-23 2022-07-12 Bristol Myers Squibb Co Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t.
CA3162979A1 (en) * 2019-12-23 2021-07-01 Upender Velaparthi Substituted piperazine derivatives useful as t cell activators
IL294148A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinazolinyl compounds are useful as t-cell activators
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
AR120896A1 (es) * 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
CA3180670A1 (en) * 2020-04-24 2021-10-28 Bayer Aktiengesellschaft Substituted aminothiazoles as dgkzeta inhibitors for immune activation
WO2021258010A1 (en) * 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
JP7604067B2 (ja) * 2020-11-26 2024-12-23 エルジー・ケム・リミテッド ジアシルグリセロールキナーゼ阻害剤としての複素環化合物及びその用途
WO2022114164A1 (ja) * 2020-11-30 2022-06-02 アステラス製薬株式会社 ヘテロアリールカルボキシアミド化合物
AU2021400725A1 (en) 2020-12-16 2023-08-03 Gossamer Bio Services, Inc. Compounds useful as t cell activators
KR20230165771A (ko) 2021-03-03 2023-12-05 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법 및 dgk 억제제의 조합
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
MX2023014762A (es) * 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
WO2023122777A1 (en) * 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
CN118946556A (zh) * 2022-02-01 2024-11-12 阿维纳斯运营公司 Dgk靶向化合物及其用途
IL315015A (en) 2022-03-01 2024-10-01 Insilico Medicine Ip Ltd Diacylglycerol kinase (DGK) alpha inhibitors and their uses
EP4486745A4 (en) * 2022-03-01 2026-03-11 Insilico Medicine Ip Ltd Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses
WO2023165525A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
WO2023184327A1 (en) * 2022-03-31 2023-10-05 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof
CN119998295A (zh) 2022-06-08 2025-05-13 因赛特公司 作为dgk抑制剂的三环三唑并化合物
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US20240083898A1 (en) * 2022-08-15 2024-03-14 Incyte Corporation Tricyclic triazolo compounds as dgk inhibitors
KR20250061756A (ko) 2022-09-08 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
CN116375654B (zh) * 2023-03-22 2024-12-31 湖北三峡实验室 一种由双甘肽制备2,5-二酮哌嗪的方法
CN119143715B (zh) * 2024-11-12 2025-03-14 天津匠新致成科技有限公司 二芳基团甲基哌嗪类化合物及其制备方法、药物组合物和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124604A1 (en) * 2003-08-22 2005-06-09 Jagadish Sircar Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
US20050266510A1 (en) * 2004-01-08 2005-12-01 Gajewski Thomas G T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
US20080139551A1 (en) * 2006-03-21 2008-06-12 Avanir Pharmaceuticals Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
WO2017177037A1 (en) * 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
CA2489560A1 (en) 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
GB0230018D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
WO2004087880A2 (en) 2003-03-26 2004-10-14 Bayer Pharmaceuticals Corporation Compounds and their use to treat diabetes and related disorders
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
CA2533626A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
JP2007308402A (ja) 2006-05-17 2007-11-29 Sumitomo Chemical Co Ltd シンナモイル化合物及びその用途
JP2007308441A (ja) 2006-05-22 2007-11-29 Sumitomo Chemical Co Ltd 含複素環化合物及びその用途
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042489A2 (en) 2008-10-06 2010-04-15 Emory University Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
IN2015DN02826A (enExample) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
US9133164B2 (en) 2011-04-13 2015-09-15 Innov88 Llc MIF inhibitors and their uses
NO2694640T3 (enExample) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
US9006257B2 (en) 2012-02-09 2015-04-14 Glenmark Pharmaceuticals S.A. Bicyclic compounds as mPGES-1 inhibitors
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
AU2016245864C1 (en) 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
CN107216325B (zh) 2016-03-22 2019-06-25 上海医药工业研究院 萘啶酮类化合物、及其制备方法和应用
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
WO2018134885A1 (ja) 2017-01-17 2018-07-26 初実 田中 支援奨励システムおよび支援奨励方法
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US12187687B2 (en) 2017-06-26 2025-01-07 University Of Virginia Patent Foundation Compositions and uses thereof
CU24684B1 (es) 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
WO2019235553A1 (ja) 2018-06-07 2019-12-12 第一三共株式会社 アゼチジン誘導体及びそのプロドラッグ
ES3032286T3 (en) 2018-06-27 2025-07-16 Biogen Ma Inc Ask1 inhibiting agents
WO2020006296A1 (en) 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
TWI833770B (zh) 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法
WO2020004594A1 (ja) 2018-06-27 2020-01-02 株式会社リボルナバイオサイエンス 脊髄性筋萎縮症の予防または治療剤
KR102698500B1 (ko) 2018-06-27 2024-08-26 주식회사 오스코텍 Axl 억제제로 사용하기 위한 피리도피리미디논 유도체
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124604A1 (en) * 2003-08-22 2005-06-09 Jagadish Sircar Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
US20050266510A1 (en) * 2004-01-08 2005-12-01 Gajewski Thomas G T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
US20080139551A1 (en) * 2006-03-21 2008-06-12 Avanir Pharmaceuticals Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
WO2017177037A1 (en) * 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer

Also Published As

Publication number Publication date
RS64641B1 (sr) 2023-10-31
US11713316B2 (en) 2023-08-01
US10669272B2 (en) 2020-06-02
TW202019924A (zh) 2020-06-01
EP3814348B9 (en) 2023-11-01
PT3814348T (pt) 2023-10-17
JP7432532B2 (ja) 2024-02-16
CL2020003260A1 (es) 2021-04-23
SI3814348T1 (sl) 2023-10-30
PE20210469A1 (es) 2021-03-08
SG11202012972YA (en) 2021-01-28
KR102767739B1 (ko) 2025-02-12
FI3814348T3 (fi) 2023-09-22
HUE064531T2 (hu) 2024-04-28
WO2020006018A1 (en) 2020-01-02
KR20210024586A (ko) 2021-03-05
JP2021529191A (ja) 2021-10-28
IL279728B2 (en) 2023-07-01
IL279728B1 (en) 2023-03-01
DK3814348T3 (da) 2023-10-30
EP3814348A1 (en) 2021-05-05
IL279728A (en) 2021-03-01
ES2960754T3 (es) 2024-03-06
AU2019291794A1 (en) 2021-02-11
SMT202300466T1 (it) 2024-01-10
MX2020013817A (es) 2021-03-09
PL3814348T3 (pl) 2023-09-11
CY1126280T1 (el) 2026-02-25
HRP20231253T1 (hr) 2024-02-02
CN112654621B (zh) 2024-05-14
US10954238B1 (en) 2021-03-23
CN112654621A (zh) 2021-04-13
ZA202100555B (en) 2022-07-27
LT3814348T (lt) 2023-10-10
US20220324859A1 (en) 2022-10-13
US20200109140A1 (en) 2020-04-09
EP3814348B1 (en) 2023-08-02
CA3104654A1 (en) 2020-01-02
BR112020026681A2 (pt) 2021-04-06

Similar Documents

Publication Publication Date Title
US11713316B2 (en) Substituted naphthyridinone compounds useful as T cell activators
US11584747B2 (en) Substituted pyridopyrimidinonyl compounds useful as T cell activators
JP7760493B2 (ja) Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
KR102808367B1 (ko) Hpk1 억제제로서 유용한 이소푸라논 화합물
CA3162979A1 (en) Substituted piperazine derivatives useful as t cell activators
BR112016008276B1 (pt) derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica
CA3214244A1 (en) Pyridinyl substituted oxoisoindoline compounds
TW202322808A (zh) 治療疾病之化合物、組合物及方法
WO2023122778A1 (en) Pyridazinone derivatives useful as t cell activators
US12145927B2 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN117157286A (zh) 经吡啶基取代的氧代异吲哚啉化合物
EA043061B1 (ru) Замещенные нафтиридиноновые соединения, полезные в качестве активаторов т-клеток

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired